Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2021 · 10-Q
Revenue$350.00K$350.00K+62.0% vs Q3 2020 Net Income$45.52M$45.52MN/M vs Q3 2020 EPS Diluted-$0.01-$0.01N/M vs Q3 2020 Operating Income-$10,049,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2871.1%+19294.1 pt vs Q3 2020
Net margin13005.4%+102864.7 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end